Notably, Tacle treatment reduced the growth of MM xenografts, with potential on-target activity as demonstrated by reduced Drp1 protein levels, even in its fission-promoting S616-phosphorylated form, along with reduced expression of c-MYC and SREBP1, in resected tumor samples, without any evidence of toxicity towards mice. This evidence concerns the gene SREBF1 and Miyoshi myopathy.